Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Stock Information for Virax Biolabs Group Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Virax Biolabs Group Limited

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Virax Biolabs Group Limited Announces $5 Million Private Placement
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune(TM) Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
Virax Biolabs Partners with Emory University on ViraxImmune(TM) Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.